These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23683110)

  • 1. Pemetrexed for the treatment of non-small cell lung cancer.
    Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of pemetrexed in the management of non-small-cell lung cancer patients.
    Tomasini P; Greillier L; Khobta N; Barlesi F
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):257-66. PubMed ID: 23477511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
    Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
    Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
    Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
    Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current state of pemetrexed in ovarian cancer.
    Miller RE; Banerjee S
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1201-10. PubMed ID: 23899335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.